Explore the latest in vaccination, including recent advances in child and adult immunization and studies of vaccine refusal and safety.
This survey study assesses the acceptability of coronavirus disease 2019 (COVID-19) vaccine mandates among members of the US public.
This Viewpoint discusses individual- and system-level barriers and solutions for people with serious mental illness to access coronavirus disease 2019 vaccination when it is available.
This JAMA Live Highlights feature provides comments about the coronavirus 2019 pandemic from experts in clinical medicine, public health, and health policy expressed during livestream interviews with JAMA Network Editor in Chief Howard Bauchner, MD.
This Viewpoint proposes behavioral economic and social marketing strategies to motivate coronavirus disease 2019 (COVID-19) vaccination among the public, including making the vaccine free and accessible, requiring it for access to valued activities or settings, and securing public endorsements from leaders or celebrities to ease perceptions of safety and acceptability.
This Viewpoint proposes that prioritizing all placebo-group participants in coronavirus vaccine trials as vaccine first receivers could perpetuate health inequities and compromise the chance to learn from their participation, proposing instead to limit prioritization to placebo participants who would be prioritized for vaccination anyway under NASEM or ACIP frameworks.
This Viewpoint discusses the ethics of including a placebo arm in randomized trials of coronavirus vaccines once authorized vaccines have become widely available, and proposes use of adaptive platform trial designs as an optimal approach to nimbly and ethically compare future investigational COVID-19 vaccines with proven effective ones.
This perspective is that of a nursing researcher turned volunteer in a COVID-19 vaccine trial. She considers the experience of study participants and how clinicians will need to prepare their patients for the vaccine’s possible adverse effects.
This study assesses the association of social distancing due to coronavirus disease 2019 (COVID-19) with immunizations administered by age category (0-2 years, 3-9 years, and 10-17 years) in Colorado.
This randomized clinical trial compares the effect of high-dose vs standard-dose influenza vaccine on all-cause mortality and hospitalizations due to cardiovascular or pulmonary causes in patients with high-risk cardiovascular disease.
This case-control study uses national hospital and immunization records in Portugal to estimates the difference in incidence of invasive group B meningococcal disease among children and adolescents who were immunized vs not immunized with 4CMenB, a 4-component meningococcus group B vaccine licensed in 2013.
This study examines the association between self-reported vision impairment and uptake of preventive care services (ie, breast and colon cancer screenings and influenza and pneumococcal vaccinations).
This cohort study uses data from the electronic health records of Kaiser Permanente Southern California members to assess whether the number of doses in a hepatitis B virus vaccine series is associated with completion of the series among US adults.
This JAMA Insights Clinical Update discusses herd immunity in the context of the COVID-19 pandemic and explains the herd immunity threshold as a function of transmissibility (R0), the role of an effective vaccine and vaccination program in sustaining herd immunity, and the risks of an infection-based herd immunity approach.
This Viewpoint considers how COVID-19 vaccines can be distributed strategically, ethically, and legally given conflicts between consensus public health recommendations to prioritize allocation to disadvantaged racial and ethnic minorities and laws discouraging explicit consideration of race in policy decisions.
This Viewpoint offers provisional answers to common questions the public will have about approved COVID-19 vaccines, including what they can expect regarding its effectiveness and safety, trustworthiness of the approval process, and whether society can return to normal once sufficient numbers of people are immunized.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: